NCT04034927 - Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

February 21, 2026

Conditions

Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid TumorOvarian High Grade Serous AdenocarcinomaPlatinum-Sensitive Fallopian Tube CarcinomaPlatinum-Sensitive Ovarian CarcinomaPlatinum-Sensitive Primary Peritoneal CarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian Serous AdenocarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Primary Peritoneal Endometrioid Adenocarcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Olaparib

Given PO

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (20)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

22908

University of Virginia Cancer Center, Charlottesville

23298

VCU Massey Comprehensive Cancer Center, Richmond

30912

Augusta University Medical Center, Augusta

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

44122

UHHS-Chagrin Highlands Medical Center, Beachwood

44195

Cleveland Clinic Foundation, Cleveland

53226

Medical College of Wisconsin, Milwaukee

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77030

M D Anderson Cancer Center, Houston

80045

UCHealth University of Colorado Hospital, Aurora

87106

University of New Mexico Cancer Center, Albuquerque

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

06102

Hartford Hospital, Hartford

02905

Women and Infants Hospital, Providence